Submitted by Erika Demachki (erikademachki@gmail.com) on 2014-10-22T16:44:26Z
No. of bitstreams: 4
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 01.pdf: 10357491 bytes, checksum: 1678b4aad93bca319ee5ddb93d3808bc (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 02.pdf: 9533486 bytes, checksum: ad5e21870e09f4f46a3045a69996aed3 (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 03.pdf: 8695341 bytes, checksum: 5f8d696c0a73f923cb129f3c0aa1e4b7 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2014-10-22T19:00:24Z (GMT) No. of bitstreams: 4
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 01.pdf: 10357491 bytes, checksum: 1678b4aad93bca319ee5ddb93d3808bc (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 02.pdf: 9533486 bytes, checksum: ad5e21870e09f4f46a3045a69996aed3 (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 03.pdf: 8695341 bytes, checksum: 5f8d696c0a73f923cb129f3c0aa1e4b7 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-10-22T19:00:24Z (GMT). No. of bitstreams: 4
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 01.pdf: 10357491 bytes, checksum: 1678b4aad93bca319ee5ddb93d3808bc (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 02.pdf: 9533486 bytes, checksum: ad5e21870e09f4f46a3045a69996aed3 (MD5)
Tese - Débora Cristina Silva dos Passos - 2013 - Parte 03.pdf: 8695341 bytes, checksum: 5f8d696c0a73f923cb129f3c0aa1e4b7 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Previous issue date: 2013-05-16 / Melanoma is a type of cancer that arises from melanocytes and is notoriously resistant to
radiation and chemotherapy. The thiosemicarbazones are synthetic compounds with marked
biological properties such as antibacterial, antiviral, antiprotozoal and antitumor and previous
studies have demonstrated cytotoxic activity against the human melanoma cells, so in this
study, we evaluated the antiproliferative activity, the enzymatic activity of Caspases 2, 3, 6, 8,
9, the effect on the cell cycle gene expression levels of caspases 2, 3, 6, 8, 9, Apaf-1 and
microscopic morphological changes in human melanoma cells (SK -MEL-37) twenty one
monoterpene derived from natural thiosemicarbazone (-) - camphene: camphene,
benzaldehyde, benzophenone, menthone, ethyl pyruvate, p-nitroacetophenone, pchloroacetophenone,
p-methoxyacetophenone, p-methylacetophenone, p fluoracetofenona-phidroxiacetofena,
furan, 3-methoxy-4-hydroxybenzaldehyde, p-fluorbenzaldehyde, 2-
hydroxybenzaldehyde, cinnamic aldehyde, thiophene-2-carboxaldehyde, 1-H-imidazole-4-
carboxaldehyde, tiossemicaroazida and six montoterpeno natural R-(+)-limonene:
benzaldehyde, thiosemicarbazide, o-nitro, m-nitro, p-nitro, p-hydroxy and p-dimethylamino.
The values found for the inhibitory concentration for 50% of cells (IC50) were between 12
μM and 55 μM. The percentage of cells in phase and in phase G0/G1 decreased SG2 / M
increased after forty-eight hours of incubation with benzaldehyde thio-camphene, limonene
thio-benzaldehyde, m-nitro, p-hydroxy and thiosemicarbazide increased indicating that the
growth inhibitory effect might be also due to arrest of cells at S-G2/M phase. We observed
increased activity of caspase 3 (m-nitro thio-limonene), 6 (camphene thio-benzaldehyde and
p-hydroxy thio-limonene) and 8 (thio-benzaldehyde limonene). Late apoptotic features were
detected in 62% of cells treated with benzaldehyde thio-camphene and morphological changes
typical of apoptosis were visualized by fluorescence microscopy and scanning electron
microscopy (SEM) after treatment with benzaldehyde thio-camphene chosen due to their low
IC50 value (12 mM). It was observed gene expression of caspases 2, 3, 6, 8 and Apaf-1 in
cells treated with benzaldehyde thio-camphene indicating the participation of these enzymes
in the anti-proliferative effect observed. Our results indicate that the thiosemicarbazones
derivatives can inhibit proliferation, regulate cell cycle, induce apoptosis of human melanoma
cells (SK-MEL-37) and could be an candidate for future preclinical in vivo studies. / O melanoma é um tipo de câncer que surge nos melanócitos e é notoriamente resistente à
radioterapia e quimioterapia. As tiossemicarbazonas são compostos sintéticos com marcantes
propriedades biológicas tais como antibacteriana, antiviral, antiprotozoária e antitumoral e em
estudos anteriores demonstraram ação citotóxica frente à celulas de melanoma humano, por
isso, neste estudo, foi avaliada a atividade anti-proliferativa, a atividade enzimática das
caspases 2, 3, 6, 8, 9, o efeito no ciclo celular, os níveis de expressão gênica das caspases 2, 3,
6, 8, 9, Apaf-1 e as alterações morfológicas por microscopia em células de melanoma humano
(SK-MEL-37) de vinte e uma tiossemicarbazonas derivadas do monoterpeno natural (-)-
canfeno: canfeno, benzaldeído, benzofenona, mentona, etil piruvato, acetofenona, pnitroacetofenona,
p-cloroacetofenona, p-metoxiacetofenona, p-metilacetofenona, pfluoracetofenona,
p-hidroxiacetofena, furano, 3-metóxi-4-hidroxibenzaldeído, pfluorbenzaldeído,
2-hidroxibenzaldeído, aldeído cinâmico, tiofeno-2-carboxialdeído, 1-Himidazol-
4-carboxialdeído, tiossemicaroazida, bem como seis do montoterpeno natural R-(+)-
limoneno: benzaldeído, tiossemicarbazida, o-nitro, m-nitro, p-nitro, p-dimetilamino e phidróxi
. Os valores encontrados para a concentração inibitória para 50% das células (IC50)
situaram-se entre 12 μM e 55 μM. A porcentagem de células na fase G0/G1diminuiu e na fase
SG2/M aumentou após quarenta e oito horas de incubação com o benzaldeído tio-canfeno,
benzaldeído tio-limoneno, m-nitro, p-hidróxi e tiossemicarbazida, indicando que o efeito
antiproliferativo observado pode ser devido a uma interrupção das células na fase SG2/M.
Observou-se uma maior atividade de caspase 3 (m-nitro tio-limoneno), 6 (benzaldeído tiocanfeno
e p-hidróxi tio-limoneno) e 8 (benzaldeído tio-limoneno). Características apoptóticas
tardias foram detectados em 62% das células tratadas com benzaldeído tio-canfeno e as
alterações morfológicas típicas de processo de apoptose foram visualizadas através da
microscopia de fluorescência e de microscopia eletrônica de varredura (MEV) após
tratamento com o benzaldeído tio-canfeno escolhido devido ao seu baixo valor de IC50 (12
μM). Observou-se a expressão gênica das caspases 2, 3, 6, 8 e o apaf-1 nas células tratadas
com benzaldeído tio-canfeno indicando a participação dessas enzimas no efeito
antiproliferativo observado. Os resultados indicam que as tiossemicarbazonas derivadas de
canfeno e limoneno podem inibir a proliferação celular, regular o ciclo celular e induzir
apoptose nas células de melanoma humano (SK-MEL-37), portanto, podem ser considerados
candidatos para futuros ensaios pré-clínico in vivo.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.bc.ufg.br:tede/3426 |
| Date | 16 May 2013 |
| Creators | Passos, Débora Cristina Silva dos |
| Contributors | Guillo, Lídia Andreu, Oliveira, Cecília Maria Alves de |
| Publisher | Universidade Federal de Goiás, Programa de Pós-graduação em Biologia (ICB), UFG, Brasil, Instituto de Ciências Biológicas - ICB (RG) |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | Portuguese |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/doctoralThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UFG, instname:Universidade Federal de Goiás, instacron:UFG |
| Rights | http://creativecommons.org/licenses/by-nc-nd/4.0/, info:eu-repo/semantics/openAccess |
| Relation | 6883982777473437920, 600, 600, 600, -3872772117827373404, 3962143990328052072, AFRASIABI, Z.; SINN, E.; CHEN, J.; MA, Y.; RHEINGOLD, A.L.; ZAKHAROV, L.N.; RATH, N. & PAHYDE, S. Appended 1,2-naphthoquinones as anticancer agents 1: synthesis, structural, spectral and antitumor activities of ortho-naphthaquinone thiosemicarbazone and its transition metal complexes. Inorganica Chimica Acta, v. 357, n. 1, p. 271-278, 2004. ALOMAR, K.; LANDREAU, A.; KEMPF, M.; KHAN, M.A.; ALLAIN, M. & BOUET, G. Synthesis, crystal structure, characterization of zinc(II), cadmium(II) complexes with 3- thiophene aldehyde thiosemicarbazone (3TTSCH). Biological activities of 3TTSCH and its complexes. Journal of Inorganic Biochemistry, v. 104, p. 397-404, 2010. ARROIO, A.; HONÓRIO, K.M.; SILVA, A.B.F. Propriedades químico-quânticas empregadas em estudos das relações estrutura-atividade. Química Nova, v.33, n. 3, p. 694-699, 2010. ATEVESER, B.; ULKUSEVEN, B.; ERDEM-KURUCA, T.B.D.S.; SOLAKOGLU, Z. Cytotoxic activities of new iron(III) and nickel (II) chelates of some S-methylthiosemicarbazones on K562 and ECV304 cells. Investigational New Drugs, v. 28, p. 421- 432, 2010. ATTIA, S.; KOLESAR, J.; MAHONEY M.R.; PITOT, H.C.; LAHERU, D., HEUN, J.; HUANG, W.; EICKHOFF, J.; ERLICHMAN, C.; HOLEN, K.D. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs, v. 26, n. 4, p. 369-379, 2008. BARROS, H.J.V.; HANSONE, B.E.; GUSEVSKAVA, E.V.; SANTOS, E.N. Biphasic hydroformylation of monoterpenes employing Rh/TPPTS/CTAC: the role of the substrate in the mass transfer between the phases. Applied Catalysis A: General, v. 278, n. 1, p. 57-63, 2004. BASOLO, F. “Frontiers in Inorganic Chemistry”. Coordination Chemistry Reviews, v. 125, n. 13, 1993. BAYLY, A. C.; ROBERTS, R. A.; DIVE, C. Mechanisms of apoptosis. In: BITTAR, E.E. Advances in molecular and cell biology. Greenwich,CT: JAI Press, 1997. v. 20, p. 183-229. BELIZÁRIO, J. E.; ALVES, J.; OCCHIUCCI, J. M.; GARAY-MALPARTIDA, M.; SESSO, A. Brazilian Journal of Medical and Biological Research, v. 40, p. 1011-1024, 2007. BERALDO, H.; KAISNER, J.D. TURNER, I.S. BILLEH, J.S. IVES, D.X. Copper(II) and nickel(II) complexes of the bis{N(3)-substituted thiosemicarbazones} of phenylglyoxal and 1- phenylpropane-1,2-dione West. Transition Metal Chemistry, v. 22, n. 5, p. 459- 464, 1997. BERALDO, H. Semicarbazonas e Tiossemicarbazonas: O amplo perfil farmacológico e Usos Clínicos. Química. Nova, v. 27, n. 3, p. 461-471, 2004. BERALDO, H. & GAMBINO, D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Reviews in medicinal chemistry, v. 4, n. 1, p. 31-39, 2004. BERNHARD, D., SCHWAIGER, W.; CRAZZOLARA, R.; TINHOFER, I.; KOFLER, R.; CSORDAS, A. Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells. Cancer Letters, v. 195, n. 2, p. 193-199, 2003. BHARTI, N.; HUSAIN, K.; GARZA, M.T.G.; VEGA, D.E.C.; GARZA, J.C.; CARDENAS, B.D.M.; NAQVI, F.; AZAM, A. Synthesis and In Vitro Antiprotozoal Activity of 5- Nitrothiophene-2-carboxaldehyde Thiosemicarbazone Derivatives. Bioorganic Medicinal Chemistry Letters, v.12, n. 23, p. 3475-3478, 2002. BHARTI, N.S.; NAQVI, F. & AZAM, A. Synthesis, spectral studies and screening for amoebicidal activity of new palladium(II) complexes derived from thiophene-2- carboxaldehyde thiosemicarbazones. Bioorganic Medicinal Chemistry Letters, n. 13, v. 4, p. 689-692, 2003. BOERSMA, H.H.; KIETTSCLAER, B.L.J.H.; STOLK, L.M.L.; BENNAGHMOUCH, A.; HOFSTRA, L.; NARULA, J.; HEIDENDAL, G.A.K.; REUTELINGSPERGER, C.P.M. Past, present, and future of annexin A5: from protein discovery to clinical applications. Journal of Nuclear Medicine, v. 46, n. 12, p. 2035-2050, 2005. BRAULT, L.; MIGIANU, E.; NÉGUESQUE, A.; BATTAGLIA, E.; BAGREL, D.; KIRSH, G. New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. European Journal of Medicinal Chemistry, v. 40, p. 757-763, 2005. CÂNCER. Disponível em: <http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/Patient > Acesso em: 07 de Abril de 2013. CARMICHAEL, J.; DEGRAFF, W.G.; GAZDAR, A.F.; MINNA, J.D. & MITCHELL, J.B. Evaluation of a Tetrazolium-based Semiautomated Colorimetrie Assay Assessment of Chemosensitivity Testing. Cancer Research, v. 47, p. 936-942, 1987. CHAMMAS, R.; DUARTE, A. P. M.; OTAKE, A. H.; COSTA, M. Genética e Biologia Molecular do Melanoma e de sua progressão. In: Melanoma Cutâneo Localizado e Linfonodo Sentinela. São Paulo: Lemar, p. 1-19, 2003. CHEN, C.N.; HUANG, H.H.; WU, C.L.; LIN, C.P.C.; HSU, J.T.A.; HSIEH, H.P.; CHUANG, S.E.; LAI, G.M. Isocostunolide, a sequiterpene lactone, induces mitocondrial membrane depolarization and caspase-dependent apoptosis in human melanoma cells. Cancer Letters, v. 246, p. 237-252, 2007. CHEN, L.H.; HU, Y.H; SONG, W.; SONG, K.K.; LIU, X.; JIA, Y. L.; ZHUANG, J.X. & CHEN, Q. X. Synthesis and Antityrosinase mechanism of Benzaldehyde Thiossemicarbazones – Novel Tyrosinase Inhibitors. Journal of agricultural and food chemistry, v. 60, n. 6, p. 1542-1547, 2012. CHINKWO, K. A. Surtherleia frutescens extracts can induce apooptosis in cultured carcinoma cells. Journal of Ethnopharmacology, v. 98, p. 163-170, 2005. CHO, S.G. & CHOI, E.J. Apoptotic signaling pathways: Caspases and Stress-Actived Prtein Kinases. Journal of Biochemistry and Molecular Biology, v. 25, p. 24-27, 2002. CHOI, E.W.; SHIN, I.S.; BHANG, D.H.; LEE, D.H.; BAE, B.K.; KANG, M.S.; KIM, D.Y.; HWANG, C.Y.; LEE, C.W.; YOUN, H.Y. Hormonal change and cytokine mRNA expression in peripheral blood mononuclear cells during the development of canine autoimmune thyroiditis. Clinical and Experimental Immunology, v. 146, n. 1, p. 101-108, 2006. COHEN, G.M. Caspases: the executioners of apoptosis. Biochemichal Journal, v. 326, p. 1- 16, 1997. COLEMAN, M.L.; SAHAI, E.A.; YEO, M.; BOSCH, M. DEWAR, A. & OLSON, M.F. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nature Cell Biology, v. 4, p. 339-345, 2001. COOPER, G.M. The Cell: a molecular Approach. 2ª ed., Boston: Sinouer Associates, 2000. CRUCHTEN, V.S. & BROECK, W.V.D. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anatomia, Histologia, Embryologia, v. 31, n. 4, p. 214-223, 2002. DE CARVALHO, D.D.; COSTA, F.T.M; DURAN, N.; HAUN, M. Citotoxic activity of violacein in human colon cancer cells. Toxicology in Vitro, v. 20, n. 8, p. 1514-1521, 2006. DEMORO, B.; ROSSI, M.; CARUSO, F.; LIEBOWITZ, D.; OLEA-AZAR, C.; KEMMERLING, U.; MAYA, J.D.; GUISET, H.; MORENO, V.; PIZZO, C.; MAHLER, G.; OUTRO, L.; GAMBINO, D. Potencial Mechanism of the Anti-trypanosomal Activity of Organoruthenium Complexes with Bioactive Thiosemicarbazones. Biological Trace Element Research, in press, 2013. DEVARAJAN, E.; SAHIN, A.A.; CHEN, J.S.; KRISHAMURTHY, R.R.; AGGARWAL, N.; BRUN, A.M.; SAPINO, A.; ZHANG, F.; SHARMA, D.; YANG, X.H.; MEHTA, K. Downregulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene, v. 21, p. 8843-8851, 2002. DHOMEN, N.; REIS-FILHO, J.S.; DIAS, S.R.; HAYWARD, R.; SAVAGE, K.; DELMAS, V.; LARUE, L.; PRITCHARD, C.; MARAIS, R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, v. 15, p. 294-303, 2009. DORTA, D.J. Efeitos citoprotetor e/ou citotóxico dos flavonóides: estudo estruturaatividade envolvendo mecanismos mitocondriais, com ênfase na apoptose. Tese de doutorado apresentada ao programa de pós-graduação em Toxicologia, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP. 2007. EARNSHAW, W.C.; MARTINS, L.M. & KAUFMANN, S.H. Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annual Reviews of Biochemistry, v. 68, p. 383-424, 1999. EDINGER, A.L. & THOMPSON, C.B. Death by design: apoptosis, necrosis and autophagy. Current Opinion in Cell Biology, v. 16, p. 663-669, 2004. ENARI, M.; SAKAHIRA, H., HOKOYAMA, H., OKAMA, K., IWAMATSU A., NAGATA,S. A caspasae-activated DNAse that degrades DNA during apoptosis and its inhibitor ICAD. Nature, v. 391, p. 43-50, 1998. ERDAL, H., BERNDTSSON, M., CASTRO, J., BRUNK, U., SHOSHAN, M.C., LINDER, S. Induction of lysosomal membrane permeabilization by compounds that activate p53- independent apoptosis. Procedings of the National Academy of Sciences, v. 102, p. 192-197, 2005. FERREIRA, C. G. & ROCHA, J. C. Oncologia Molecular. São Paulo: Atheneu, 2004. 469 p. FEUN, L.; MODIANO, M.; LEE, K.; MAO, J.; MARINI, A.; SAVARAJ, N.; PLEZIA, P.; ALMASSIAN, B.; COLACINO, E.; FISHCHER, J.; MACDONALD, S. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemotherapy Pharmacological, v. 50, n. 3, p. 223-229, 2002. FLOYD, A.B.; THESSINGA, J.; STOTTA, A.; HOLDERB, A.A.; POLUEKTOVC, O.G.; LID, L.; SEERAM, N.P. Anticancer activity and biophysical reactivity of copper complexes of 2-(benzo[d][1,3]dioxol-5-ylmethylene)-Nalkylhydrazinecarbothioamides. National of Health Intitutes, v. 15, p. 225-229, 2013. FOSTER, I. Cancer: A cell cycle defect. Radiography, v. 14, p. 144-149, 2008. GARCIA-TOJAL, J; GARCÍA-ORAD, A.; ALVAREZ-DÍAZ, A.; SERRA, J. L.; URTIAGA, M. K.; ARRIORTUA, M. I.; ROJO, T. Biological activity of complexes derived from pyridine- 2-carbaldehyde thiosemicarbazone. Journal of Inorganic Biochemistry, v. 84, n. 3-4, p. 271- 278, 2001. GLISONI, R.J.; GARCÍA-FERNANDEZ, M.J.; PINO, M.; GUTKIND, G.; MOGLIONI, A.G.; ALVAREZ-LORENZO, C.; CONCHEIRO, A.; SOSNIK, A. β-Cyclodextrin hydrogels for the ocular release of antibacterial thiosemicarbazones. Carbohydrate Polymers, v. 93, n. 2, p. 449-457, 2013 GHOBRIAL, I.M.; WITZING, T.E.; ADJEI, A.A. Targeting apoptosis pathways in cancer therapy. A Cancer Journal of Clinicians, v. 55, p. 178-194, 2005 GILES, F.J. A new era for ribonucleoside reductase inhibition. Leukemia research, v. 31, n. 9, p. 1163-1164, 2007. GRAY-SCHOPFER, V.; WELLBROCK, C.; MARAIS, R. Melanoma biology and new targeted therapy. Nature, v. 445, p. 851 -857, 2007. GREEN, D. & KROEMER, G. The central executioners of apoptosis: caspases or mitochondria. Trends in Cell Biology, v. 8, p. 267–271, 1998. GREENBAUN, D.C.; MACKEY, Z.; HANSELL, E.; DOYLE, P.; GUT, J.; CAFFREY, C.R.; LEHRMAN, J.; ROSENTHAL, P.J.; MCKERROW, J.H.; CHIBALE, K. Synthesis and Structure-Activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei and Trypanosoma cruzi. Journal of Medicinal Chemistry, v. 47, p. 3212-3219, 2004. GRIVICICH, I.; REGNER, A.; ROCHA, A. B. Morte celular por apoptose. Revista Brasileira de Cancerologia, v. 53, p. 335-343, 2007. GRUBER, F.P & HARTUNG, T. Alternatives to animal experimentation in biomedical education. Altex, v. 21, p. 33-48, 2004. GUICCIARDI, M.E.; DEUSSING, J.; MIYOSHI, H.; BRONK, S.F.; SVINGEN, P.A.; PETERS, C.; KAUFMANN, S.H.; GORES, G.J. Cathepsin B contributes to TNF-alphamediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. Journal of Clinical Investigation, v. 106, n. 9, p. 1127-1137, 2000. GUSEVSKAYA, E.V.; dos SANTOS, E.N.; AUGUSTI, R.; DIAS, A.O.; FOCA, C.M. Platinum/estanho catalisada hidroformilação de monoterpenos naturais. Journal of Molecular Catalysis A: Chemical, v. 152, n.1-2, p. 15-24, 2000, HAIL J. R, N.; CARTER B. Z.; KONOPLEVA, M.; ANDREEFF, M. Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis, v. 11 p. 889–904, 2006. HAJRA, K. M.; LIU, J. R. Apoptosome dysfunction in human cancer. Apoptosis. v. 9, p. 691- 704, 2004. HAMRE, D.; BERNSTEIN, J. & DONOVICK, R. The chemotherapy of experimental tuberculosis. II Thiosemicarbazones and analogues in experimental tuberculosis in the mouse. Proceeding of Society for Experimental Biology and Medicine, v. 73, p. 275-280, 1950. HANG, H.C & BERTOZZI, C.R. Chemoselective approaches to glycoprotein assembly. Accounts of Chemical Research, v. 34, p. 727-736. 2001. HARA, M.; HIGUCHI, A.; TANIZAWA, T.; OKADA, T. Clinical usefulness of cellulose acetate electrophoresis as a screening of proteinuria in childhood. The International of Pediatric Nephrology, v. 6, n. 2, p. 111-116, 1985. HEFFETER, P.; PIRKER, C.; KOWOL, C.R.; HERRMAN, G.; DORNETSHUBER, R.; MIKLOS, W.; JUNGWIRTH, U.; KOELLENSPERGER, G.; KEPPLER, B.K.; BERGER, W. Impact of terminal dimethylation on the resistance profile of α-N-heterrocyclic thiosemicarbazones. Biochemical Pharmacology, v. 83, n. 12, p. 1623-1633, 2012. HENGARTNER, M. O. The biochemistry of apoptosis. Nature, v. 407, n. 6805, p. 685-687, 2000. HENRIQUES-PONS, A. & OLIVEIRA, G.M. Is the Fas/Fas-l pathway a promising target for treating inflammatory heart disease? Journal of Cardiovascular Pharmacology, v. 53, n. 2, p. 94-99, 2009. INCA. Disponível em: <http://www.inca.gov.br/estimativa/2012/tbregioes/consolidado.asp> acesso em: 07 de Abril de 2013 JORDÁN, J.; GALINDO, M.F.; CEÑA, V.; GONZÁLEZ-GARCÍA, C. Cisteína proteasas y neurodegeneración. Revista Neurociências, v. 31, n. 4, p. 333-340, 2000. KALAIVANI, P.; PRABHAKARAN, R.; DALLEMER, F.; POORNIMA, P.; VAISHNAVI, E.; RAMACHANDRAN, E.; VIJAVA, P.V.; RENGANATHAN, R & NATARAJAN, K. DNA, protein binding, cytotoxic, cellular uptake and antibacterial activities of new palladium (II) complexes of thiosemicarbazones ligands: effects of substitution on biological activity. Metallomics, v. 4, p. 101-113, 2012. KALINOWSKI, D. & RICHARDSON, D. The evolution of iron chelators for the treatment of ironoverload disease and cancer. Pharmacological Reviews, v. 57, p. 547–583, 2005. KAMRAN, M.Z. & GUDE, R.P. Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomedicine & Pharmacotherapy, v. 66, p. 617-626, 2012 KARALI, N. Synthesis and primary cytotoxicity evaluation of new 5-nitroindole-2,3-dione derivatives. European Journal Medicinal Chemistry, v. 37, n. 11, p. 909-918, 2002. KARLSSON, M.G.; DAVIDSSON, A.; VIALE, G.; GRAZIANI, D.; HELLQUIST, H.B. Nasal messenger RNA expression of interleukins 2, 4 and 5 in patients with allergic rhinitis. Diagnostic Molecular Pathology, v. 4, n. 2, p. 85-92, 1995. KASHANI-SABET, M.; RANGEL, J.; TORABIAN, S.; NOSRATI, M.; SIMKO, J.; JABLONS, D.M.; MOORE, D.H.; HAQQ, C.; MILLER JR, 3RD.; SAGEBIEL, R.W. A multimarker assay to distinguish malignant melanomas from benign nevi. Procedings of the National Academy of Sciences, v. 106, n. 15, p. 6268-6272, 2009. KASUGA, N. C.; SEKINO, K.; ISHIKAWA, M.; HONDA, A.; YOKOYAMA, M.; NAKANO, S.; SHIMADA, N.; KOUMO, C.; NOMIYA, K. Synthesis, structural characterization and antimicrobial activities of 12 zinc(II) complexes with four thiosemicarbazone and two semicarbazone ligands. Journal of Inorganic Biochemistry, v. 96, n. 2-3, p. 298-310, 2003. KAUFMANN, S.H.; LEE, S.H.; MENG, X.W.; LOEGERING, D.A.; KOTTKE, T.J.; HENZING, A.J.; RUCHAUD, S.; SAMEJIMA, K. & EARNSHAW. W.C. Apoptosisassociated caspase activation assays. Methods, v. 44, p. 262-272, 2008. KAVURMA, M.M.; TAN, N.Y.; BENNETT, M.R. Death receptors and their ligands in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, v. 28, p. 1694-1702, 2008. KERR, J.F.; WYLLIE, A.H. & CURRIE, A.R. A basic biological phenomenon with wide ranging implications in tissue kinetics. British Journal of Cancer, v. 26, p. 239-257, 1972. KERR, J. F.R.; GOBE, G. C.; WINTERFORD, C. M.; HARMON, B. V. Anatomical methods in cell death. Methods in Cell Biology, v. 46, p. 1–27, 1995. KNOX, J.J.; HOTTE, S.J.; KOLLMANNSBERGER, C., WINQUIST, E.; FISHER, B.; EISENHAUER, E.A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Investigational New Drugs, v. 25, n. 5, p. 471–477, 2007. KONSTANTINOVIC, S. S.; RADOVANOVICK, B. C.; KARKLJES, A. Thermal behaviour of Co(II), Ni(II), Cu(II), Zn(II), Hg(II) and Pd(II) complexes with isatin-β-thiosemicarbazone. Journal of Thermal Analysis and Caloriumetry, v. 90, n. 2, p. 525-531, 2007. KOVALA-DEMERTZI, D.; ALEXANDRATOS, A.; PAPAGEORGIOU, A.; NATH YADAV, P.; .DALEZIS, P. & DEMERTZIS, M.A. “Synthesis, characterization, crystal structures, in vitro and in vivo antitumor activity of palladium(II) and zinc(II) complexes with 2-formyl and 2-acetyl pyridine N(4)-1-(2-pyridyl)-piperazinyl thiosemicarbazone,” Polyhedron, v. 27, n. 13, p. 2731–2738, 2008. KROEMER, G.; LORENZO, G.; BRENNER, C. Mitochondrial Membrane Permeabilization in Cell Death. Physiological Reviews, v. 87, n. 1, p. 99–163, 2007. KROEMER, G.; GALLUZZI, L.; VANDENABEELE, P.; ABRAMS, J.; ALNEMRI, E.S.; BAEHRECKE, E.H.; BLAGOSKLONNY, M.V.; EL-DEINY, W.S.; GOLSTEIN, P.; GREEN, D.R.; HENGARTNER, M.; KNIGHT, R.A.; KUMAR, S.; LIPTON, S.A.; MALORNI, W.; NUÑEZ, G.;PETER, M.E.; TSCHOPP, J.; YUAN. J.; PIACENTINI, M.; ZHIVOTOVSKY, B.; MELINO, G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. National of Health Institutes, v. 16, n. 1, p. 3-11, 2009. KRUIJFF, S. & HOESKSTRA, H.J. The current status of S-100B as a biomarker in melanoma. European Journal of Surgical Oncology, v. 38, p. 281-285, 2012. KUIDA, K.; HAYDAR, T.F.; KUAN, C.Y.; GU, Y.; TAYA, C.; KARASUYAMA, H.; SU, M.S.S.; RAKIS, P. & FLAVELL, R.A. Reduced apoptosis and cytochrome-c-mediated caspase activation in mice lacking caspase 9. Cell, v. 94, p. 325–337, 1998. LESSA, J.A.; REIS, D.C.; MENDES, I.C.; SPEZIALI, N.V.; ROCHA, L.F.; PEREIRA, V.R.A.P.; MELO, C.M.L.; BERALDO, H. Antimony (III) complexes with pyridine-derived thiosemicarbazones: Structural studies and investigation on the antitrypanosomal activity. Polyhedron, v.30, p. 372-380, 2011. LI, G. & HERLYN, M. Dynamics of intercellular communication during melanoma development. Molecular Medicine, v. 6, p. 163-169, 2000. LI, M.X.; ZHOU, J.; WANG, Z.L & WANG, J.P. Synthesis, Crystal Structure and Antitumor Study of a Cobalt(II) Complex of the 2-Acetylpyrazine Thiosemicarbazone. Zeitschirift fur Naturforschung, v. 63b, p. 280, 2008. LI. M.X.; CHEN, C.L.; ZHANG, D.; NIU, J.Y. & JI, B.S. Mn(II), Co(II) and Zn(II) complexes with heterocyclic substituted thiosemicarbazones: Synthesis, characterization, X-ray crystal structures and antitumor comparison. European Journal of Medicinal Chemistry, v. 45, p. 3169-3177, 2010. LI, Y.; YANG, M.; LI, M.; YU, H.; WU, H.C.; XIE, S.Q. Synthesis, crystal structure and biological evaluation of a main group seven-coordinated bismuth(III) complex with 2- acetylpyridine N4-phenylthiosemicarbazone. Bioorganic & Medicinal Chemistry Letters, v. 23, n. 8, p. 2288-2292, 2013. LIN, K.Y. & FISHER, D.E. Melanocyte Biology Skin Pigmentation. Nature, v. 445, p. 843- 850, 2007. LINOS, E.; SWETTER, S.M.; COCKBURN, M.G.; COLDITZ, G.A.; CLARKE, C.A. Increasing burden of melanoma in the United States. Journal of Investigative Dermatology, v. 129, p. 1666-1674, 2009. LIU, M.; LIN, T.; SARTORELLI, A.C. Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiose micarbazone. Journal of Medicinal Chemistry, v. 35, p. 3672-3677, 1992. MACKLIS, J.D. & MADISON, R.D. Progressive incorporation of propidium iodide in cultured mouse neurons correlates with declining electrophysiological status: a fluorescence scale of membrane integrity. Journal of Neuroscience Methods, v. 31, p. 43-46, 1990. MAN, D.R.; ROCHA, A.B. & SCHWARTSMANN, G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anticancer compounds. The Oncologist, v. 5, p. 185-198, 2000. MANNHEIMER W. Microscopia dos Materiais - Uma Introdução. 1ª edição. Rio de Janeiro: Sociedade Brasileira de Microscopia e Microanálise , e-papers, 226p, 2002. MARTIN, S.J.; REUTELINGSPERGER, C.P.; MCGAHON, A.J.; RADER, J.A.; VAN SCHIE, R.C.; LAFACE, D.M. & GREEN, D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of Experimental Medicine, 182: 1545–1556, 1995. MELANOMA. Disponível em: <http://medfoco.com.br/fotos-de-melanoma-cancer-de-pele> acesso em: 07 de Abril de 2013 MELANOMA in situ. Disponível em: <http://www.cosmetic-lasersurg.com/main/medicaldermatology/ cancer/melanoma.html > acesso em: 07 de Abril de 2013. MENDES, I.C.; TEIXEIRA, L.R.; LIMA, R.; BERALDO, H.; SPEZIALI, N.L. & WEST, D.X. Structural and spectral studies of thiosemicarbazones derived from 3- and 4- formylpiridine and 3- and 4-acetylpyridine. Journal of Molecular Structure, v. 559, p. 355- 360, 2001. MESTER, J.; REDEUILH, G. Proliferation of breast cancer cells: regulation, mediators, targets for therapy. Anticancer Agents in Medicinal Chemistry, v. 8, p. 872-885, 2008. MILAN, A. & HUERTA, S. Apoptosis-inducing factor and colon câncer. Journal of surgical research, v. 151, n. 1, p. 163-170, 2009. MINKO, T.; KOPECKOVA, P.; KOPECEKA, J. Preliminary evaluation of caspasesdependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. Journal of Controlled Release, v. 71, p. 227–237, 2001. MOHR, P.; EGGERMONT, A.M.M.; HAUSCHILD, A.; BUZAID, A. Staging of cutaneous melanoma. Annals of Oncology, v. 20, n. 6, p. 14-21, 2009. MOSMANN, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, v. 65, n. 1-2, p. 55- 63, 1983. MOSSMAN, T.R. & SAD, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology Today, v. 17, p. 138-146, 1996. MORTON, D.L.; ESSNAR, R.; KIRDWOOD, J.M.; WOLLONAN, R.C. Malignant melanoma. In: Cancer medice, Canadá: BC Decker, p. 1849-1869, 2000. MOUSTAID, A.S. & KRZESLAK, M. Application of evolutionary games to modeling carcinogenesis. Mathematical Biosciences and Engineering, v. 10, n. 3, p. 873-911, 2013. NICOTERA, P.; LEIST, M.; FERRANDO-MAY, E. Intracellular ATP, a switch in the decision between apoptosis and necrosis. Toxicology Letters, v. 102–103, p. 139–142, 1998. ODENIKE, O.M.; LARSON, R.A.; GAJRIA, D.; DOLAN, M.E.; DELANEY ,S.M.; KARRISON, T.G., RATAIN, M.J. & STOCK, W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational New Drugs, v. 26, n. 3, p. 233-239, 2008. OTAKE, A. H. Papel de dissialogangliosídeos na proliferação e morte celular induzida de melanócitos e melanomas in vitro. Tese apresentada ao Programa de Pós-graduação em Oncologia Experimental, Faculdade de Medicina, USP, 2005. ORVIG, C. & ABRAMS M.J. Medicinal inorganic chemistry: Introduction. Chemical Reviews, v. 99, p. 2201-2203, 1999. PLASIER, B.; LLOYD, D.R.; PAUL, G.C.; THOMAS, C.R.; AL-RUBEAI, M. Automatic image analysis for quantification of apoptosis in animal cell culture by annexin-V affinity assay. Journal of immunological methods, v. 229, p. 81-95, 1999. POLO, R.A.G.; BOYA, P.; PAULEAU, A.L.,; JALIL, A.; LAROCCHETTE, N.; SOUQUÉRE, S.; ESKELINEN, E.L.; PIERRON, G.; SAFTIG, P.; KROEMER, G. The apoptosis/autophagy paradox: autophagicvacuolization before apoptotic death. Journal of Cell Science, v.118, p. 3091-3102, 2005. PUNTEL, G.O.; CARVALHO, N.R.; GUBERT, P.; PALMA, A.S.; CORTE, C.L.; ÁVILA, D.S.; PEREIRA, M.E.; CARRATU, V.S.; BERSOLIN, L.; ROCHA, J. B.; SOARES, F. A. Butane-2,3-tionethiosemicarbazone: an oxime with antioxidant properties. Chemico-biological interactions, v. 177, n. 2, p. 153-160, 2009. RABELO, F.E. & FRAGA, S. Fundamentos de medicina cutânea. 1ª edição. Rio de Janeiro: Guanabara Koogan, 1970. RABINOVITCH, P. S. DNA Content Histogram and Cell-Cycle Analysis. In Cell Death. Schwartz, L.M. and Osborne, B.A. (eds.) Methods in Cell Biology, 41, Ed. Academic Press, San Diego, p. 263-295, 1995. RELLO, S.; STOCKERT, J.C.; MORENO, V.; GÁMEZ, A.; PACHECO, M.; JUARRANZ, A.; CANETE, M. & VILLANUEVA, A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis. International journal on programmed cell death, v. 10, p. 201-208, 2005. RIGGS, D. R.; JACKSON, B. J.; VONA-DAVIS, L.; NIGAM, A.; MCFADDEN, D. W. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis. The American Journal of Surgery, v. 189, p. 680-684, 2005. ROGERO, S.O.; HIGA, O.Z.; SAIKI, M.; CORREA, O.V.; COSTA, I. Cytotoxicity due to corrosion of ear piercing studs. Toxicology in vitro, v. 14, n. 6, p. 497-504, 2000. ROGERO, S.O.; LUGÃO, A.B.; IKEDA, T.I.; CRUZ, A.S. Testes in vitro de citoxicidade, estudo comparativo entre duas metodologias. Materials Research, v. 6, n. 3, p. 317-320, 2003. RUCHAUD, S.; KORFALI, N.; VILLA, P.; KOTTKE, T.J.; DINGWALL, C.; KAUFMANN, S.H. & EARNSHAW, W.C. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. The EMBO Journal, v. 21, n. 8, p. 1967-1977, 2002. SALVARANI, F.M.; LOBATO, Z.I.P.; ASSIS, R.A.; LIMA, C.G.R.D.; SILVA, R.O.S.; PIRES, P.S.; LOBATO, F.C.F. Avaliação in vitro de toxoide alfa de Clostridium septicum. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, v.62, n. 4, p. 778-783, 2010. SAMPATH, K.; SATHIYARAJ, S.; JAYABALAKRISHNAN, C. DNA binding, DNA cleavage, antioxidant and cytotoxicity studies on ruthenium (II) complexes of benzaldehyde 4- methyl-3-thisemicarbazones, Spectrochimica Acta, v. 15, n. 105 SARTORELLI, A.C.; AGRAWAL, K.C.; TSHTSOGLU, A.S.; MOORE, E.C. Characterization of the biochemical mechanism of action of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Advances in Enzyme Regulation, v. 15, p. 117-139, 1977. SCHULER, M. & GREEN, D.R. Mechanism of p53-dependent apoptosis. Biochemical Society transactions, v. 29, p. 684-688, 2001. SCHWEIZER, D. Reverse fluorescent chromosome banding with chromomycin and DAPI. Chromosoma, v. 58, p. 307-324, 1976. SHAO, J.; ZHOU, B.; DI BILIO, A.J.; ZHU, L.; WANG, T.; QI,C.; SHIH, J.; YEN, Y. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Cancer Theraphy, v. 5, n. 3, p. 586-592, 2006. SILVA, C.C.; SILVA, A.P.B.; TANAKA, A.B.E, C.M.; SILVA, E.L.; CUNHA, S.D. & VANDRESEN, F. Síntese e avaliação da toxicidade frente a Artemia salina de novas tiossemicarbazonas derivadas de limoneno. In: 13ª SBQSUL, Florianópolis. Livro de resumos da 13ª SBQSUL, 2005. SILVA, A.P.; MARTINI, M.V.; OLIVEIRA, C.M.A; CUNHA, S.; CARVALHO, J.E.; RUIZ, A.L.T.G. & SILVA, C.C. Antitumor activity of (-)-α-bisabolol-based thiosemicarbazones against human tumor cell lives. European Journal of Medicinal Chemistry, v. 45, p: 2987- 2993, 2010. SLOMINSKI, A.; TOBIN, D.J.; SHIBAHARA, S. & WOTSMAN, J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiological Reviews, v. 84, n. 4, p. 1155- 1228, 2004. SMITH, P.K.; KROHN, R.I.; HERMANSON, G.T.; MALLIA, A.K.; GARTNER, F.H.; PROVENZANO, M.D.; FUJIMOTO, E.K.; GOEKE, N.M.; OLSON, B.J. & KLENK, D.C. Measurement of protein using bicinchoninic acid. Analytical Biochemistry, v. 150, n. 1, p. 76-85, 1985. SOARES, P.R.O. Atividade Antiproliferativa de Benzaldeído Canfeno Tiossemicarbazonas em células de Melanoma Humano (SK-MEL-37). Dissertação de mestrado apresentada ao Programa de Pós-graduação em Biologia Molecular, Instituto de Ciências Biológicas, UFG, 2008. SOENGAS, M.S. & LOWE, S.W. Apoptosis and melanoma chemoresistance. Oncogene, v. 22, p. 3138-3151, 2003. STAUB, I.; CRUZ, A.S.; PINTO, T.J.A.; SCHAPOVAL, E.E.S.; BERGOLD, A.M. Determinação da segurança biológica do xampu de cetoconazol: teste de irritação ocular e avaliação do potencial de citotoxicidade in vitro. Revista Brasileira de Ciências Farmacêuticas, v. 43, n. 2, p. 301-307, 2007. STORR,T.; THOMPSON, K.H.; ORVIG,C. Design of targeting ligands in medicinal inorganic chemistry. Chemical Society Reviews, n. 35, n. 6, p. 534-544, 2006. SYNG-AI, C.; KUMARI, A.L. & KHAR, A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Molecular Cancer Therapeutics, v. 3, n. 9, p. 1101-1108, 2004. TEITZ, Y.; RONEN, D.; VANSOVER, A.; STEMATSKY, T.; RIGGS, J. L. Inhibition of human immunodeficiency virus by N-methylisatin-beta 4':4'-diethylthiosemicarbazone and Nallylisatin- beta-4':4'-diallythiosemicarbazone. Antiviral Research, v. 24, n. 4, p. 305-314, 1994. TENÓRIO, R.P. & GÓES, A.J.S. Tiossemicarbazonas: métodos de obtenção, aplicações sintéticas e importância biológica. Química Nova, v. 28, n. 6, p. 1030-1037, 2005. UEHARA, T.; KIKUCHI, Y.; NOMURA, Y. Caspase Activation Accompanying Cytochrome c Release from Mitochondria Is Possibly Involved in Nitric Oxide-Induced Neuronal Apoptosis in SH-SY5Y Cells. Journal of Neurochemistry, v. 72, p. 196–205, 1999. VAN BRAKEL, R.; VULDERS, C.; BOKDAM, R.J.; GRULL, H.; ROBILLARD, M.S. A doxorrubicin prodrug activated by the Staudinger reaction. Bioconjud Chemistry, v. 19, p. 714- 718, 2008. VECHIA, D.L.; GNOATTO, S.C.; GOSMANN, G. Derivados oleananos e ursanos e sua importância na descoberta de novos fármacos com atividade antitumoral, anti-inflamatória e antioxidante. Química Nova, v. 32, n. 5, p. 1245-1252. 2009. WALCOURT, A.; LOYEVSKY, M.; LOVEJOY, D.B.; GORDEUK, V.R.; RICHARDSON, D. R. Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and sensitive parasites. The international of Journal of Biochemistry & Cell Biology, v. 36, n. 3, p. 401-407, 2004. WALCZAK, H. & KRAMMER, P.H. The CD95 (APO-1/Faz) and TRAIL (APO-2L) apoptosis systems. Experimental Cell. Research, v. 256, p. 58-66, 2000. WHITNALL, M.; HOWARD, J.; PONKA, P.; RICHARDSON, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcome resistance to chemotherapeutics. Procedings of the National Academy of Sciences, v. 103, p. 1491-1496, 2006. WNUK, S.F. & ROBINS, M.J. Ribonucleotide reductase inhibitors as anti-herpes agents. Antiviral Research, v. 71, n. 2-3, p. 122-126, 2006. YU, Y.; KALINOWSKI, D.S.; KOVACEVIC, Z.; SIAFAKAS, A.R.; JANSSON, P.J.; STEFANI, C.; LOVEJOY, D.B.; SHARPE, P.C.; BERNHARDT, P.V.; RICHARDSON, D.R. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. Jounal of Medicinal Chemistry, v. 52, n. 17, p. 5271- 5294, 2009 YU, Y.; GUTIERREZ, Z.; SALETTA, P.; OBEIDY, P.; RAHMANTO, Y.S.; RICHARDSON, D.R. Iron Chelators for the Treatment of Cancer. Current Medicinal Chemistry, v. 19, p. 2689-2702, 2012. YUAN, J., LOVEJOY, D. B. & RICHARDSON, D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, v. 104, p. 1450-1458, 2004. YU, Y.; RAHMANTO, Y.S.; CLARE L.H.; RICHARDSON, D.R. The Potent and Novel Thiosemicarbazone chelators, Dp44mT and Bp44mT, Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. Molecular pharmacology, v. 79, n. 6, p. 921-931, 2011. ZAMARIN, D.; VIGIL, A.; K |
Page generated in 0.0085 seconds